FOLH1 and COVID-19: Given the significantly higher [18F]-PSMA uptake of prostatic cancer lymph node metastases compared to “reactive” nodes after COVID-19 vaccination and the overall sparsity of axillary prostate cancer lymph node metastases, no therapeutic and diagnostic dilemma is to be expected.